1,004 results on '"Zent, Clive"'
Search Results
2. Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
3. Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of Lymphoma
4. Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population
5. Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
6. Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions
7. The role of splenectomy in management of splenic B-cell lymphomas
8. Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia
9. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
10. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
11. Targeted therapy for treatment of patients with classical hairy cell leukemia
12. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma
13. Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience
14. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels
15. Antibody‐mediated phagocytosis in cancer immunotherapy
16. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms
17. Chronic lymphocytic leukaemia
18. Management of melanoma in patients with chronic lymphocytic leukemia
19. First dose infusion reaction during anti-CD20 monoclonal antibody therapy in chronic lymphocytic leukemia associates with high IP-10 levels amid cytokine release syndrome
20. Indolent B-cell splenic lymphomas have T cells with an exhausted phenotype
21. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
22. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
23. Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
24. Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis
25. The Chimeric Genes AML1/MDS1 and AML1/EAP Inhibit AML1B Activation at the CSF1R Promoter, but Only AML1/MDS1 has Tumor-Promoter Properties
26. Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment
27. The Role of Splenectomy in Management of Splenic B-Cell Lymphomas
28. Innate Immune Microenvironment of Indolent B Cell Splenic Lymphomas: Role in Diagnosis and Treatment
29. Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions
30. Corrigendum to “Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia” [Leuk. Res. 120 (2022) 106919]
31. Development of a distributed international patient data registry for hairy cell leukemia
32. Long‐term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma.
33. Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.
34. PO-654-04 RISK OF NEW ONSET ATRIAL FIBRILLATION ASSOCIATED WITH CONTEMPORARY TREATMENT OF LYMPHOMA
35. Complement-dependent phagocytosis as a regulator of antibody-dependent cellular cytotoxicity
36. Persistent polyclonal B‐cell lymphocytosis: Illustration of the great mimicker of low‐grade B‐cell lymphoma
37. Ibrutinib therapy for lymphoplasmacytic lymphoma
38. Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity
39. The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
40. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia
41. Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
42. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)
43. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells
44. Recurrent Fevers, Cough, and Pulmonary Opacities in a Middle-Aged Man
45. Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL)
46. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome
47. The physician–patient relationship and quality of life: Lessons from chronic lymphocytic leukemia
48. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis
49. Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia
50. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.